DLL4 and familial pancreatic carcinoma: (iii) MEDI0639, an anti-Dll4 mAb, was tested on clinical trials for solid tumors [43], and (iv) demcizumab, an anti-Dll4 mAb, was clinically tested in non-small cell lung cancer (NSCLC) [44], pancreatic cancer, primary peritoneal carcinoma [45], and other solid tumors [46].